Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

Fig. 2

NAbs levels as measured by using a high-throughput ACE2 binding inhibition surrogate neutralization assay in convalescent versus naïve (part of data for this group were reported in [20]) vaccinated recipients; NAbs were assayed in all participating individuals (see also, Fig. 1) at D1–D50. POS, convalescent recipients of group 1 (P1) being also positive for anti-S-RBD IgGs and group 2 (P2) found negative for anti-S-RBD IgGs at D1 (indicated with distinct coloring at D1–D22); NEG, NAbs at D1 naïve recipients. All other indications are as in Fig. 1; the red arrow indicates the same donor as in Fig. 1. For NEG donors, D1 or D8 versus D36, D50, P< 0.0001 (not indicated)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us